Report Summary
GBI Research, the leading business intelligence provider, has released its latest research, Solid Organ Transplant Immunosuppressant Market to 2018 – Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods, which provides insight into the global solid organ transplant immunosuppressant drug market until 2018. The report provides an in-depth analysis of the following five transplant areas: heart, lung, pancreas, liver and kidney. It also details immunosuppressant drug markets in the following key regions: the US, the top five countries of Europe and Japan. The report also includes details about immunosuppressant drug R&D pipelines. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. GBI Research analysis shows that the global market for immunosuppressant drugs used in transplants is projected to increase at a compound annual growth rate (CAGR) of 6.7% from 2004–2010. The market is forecast to grow at a CAGR of 6.1% from 2010–2018, to reach a value of $5.6 billion in 2018. GBI Research analysis found the R&D pipeline for the immunosuppressant drug market to be moderate. The leading companies in this market, F. Hoffman La Roche, Novartis AG, Genzyme Corporation and Astellas Pharma Inc., are also analyzed in this report.
Scope
- Analysis of the five major solid organ immunosuppressant drugs market which include heart transplant, pancreas transplant, lung transplant, kidney transplant and liver transplant immunosuppressant drug market
- Data and analysis of the immunosuppressant drug market in the leading regions of the world: the US, the top five countries of Europe and Japan.
- Annualized market data for the immunosuppressant drug market from 2004–2010, with forecasts to 2018.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and target populations.
- Key drivers and restraints that have had a significant impact on the market.
- Pipeline analysis of the immunosuppressant drug market for the five types of transplant.
- Competitive landscape of the global immunosuppressant drug market including benchmarking of top companies. The key companies studied in this report are: F. Hoffman La Roche, Novartis AG, Genzyme Corporation and Astellas Pharma Inc.
Solid Organ Transplant Immunosupressants Market
Published: January 2012
Price: Single User License – US$ 3500 Corporate User License US$ 10500
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Solid Organ Transplant Immunosuppressant Market to 2018 – Executive Summary
2.1 The Global Immunosuppressant Drugs Market will Grow Steadily with Few Promising Products in the Pipeline
2.2 Limited Supplies of Organs Drives Procurement and Preservation Techniques
2.3 Market Share of Immunosuppressant Drugs in Japan is Low Due to Ethical, Religious and Philosophical Barriers
3 Solid Organ Transplant Immunosuppressant Market to 2018 – Introduction
3.1 Overview
3.2 GBI Research Report Guidance
4 Solid Organ Transplant Immunosuppressant Market to 2018 – Market Overview
4.1 Introduction
4.1.1 Types of Transplant
4.1.2 Transplant Rejection
4.1.3 Immunosuppressive Drug Therapy
4.2 Market Forecast
4.2.1 Market Share by Disease Sector
4.2.2 Market Share by Geography
4.3 Annual Cost of Therapy
4.4 Target Population
4.5 Solid Organ Transplant Immunosuppressant Market Drivers and Restraints
4.5.1 Drivers
4.5.2 Restraints
5 Solid Organ Transplant Immunosuppressant Market to 2018 – Geographical Landscape
5.1 The US
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Annual Cost of Therapy
5.1.4 Target Population
5.2 Top Five Countries of Europe
5.2.1 Introduction
5.2.2 Revenue
5.2.3 Annual Cost of Therapy
5.2.4 Target Population
5.3 Japan
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Therapy
5.3.4 Target Population
6 Solid Organ Transplant Immunosuppressant Market to 2018 – Therapeutic Landscape
6.1 Heart Transplant Market
6.1.1 Introduction
6.1.2 Revenue
6.1.3 Annual Cost of Therapy
6.1.4 Target Population
6.2 Lung Transplant Market
6.2.1 Introduction
6.2.2 Revenue
6.2.3 Annual Cost of Therapy
6.2.4 Target Population
6.3 Kidney Transplant Market
6.3.1 Introduction
6.3.2 Revenue
6.3.3 Annual Cost of Therapy
6.3.4 Target Population
6.4 Liver Transplant Market
6.4.1 Introduction
6.4.2 Revenue
6.4.3 Annual Cost of Therapy
6.4.4 Target Population
6.5 Pancreas Transplant Market
6.5.1 Introduction
6.5.2 Revenue
6.5.3 Annual Cost of Therapy
6.5.4 Target Population
7 Solid Organ Transplant Immunosuppressant Market to 2018 – Product Pipeline Analysis
7.1 Research and Development (R&D) Pipeline by Indication
7.2 R&D Pipeline by Phase
7.3 R&D Pipeline – Heart Transplant
7.3.1 Overview
7.3.2 Pre-Clinical Phase
7.3.3 Phase II
7.3.4 Phase III
7.4 R&D Pipeline – Lung Transplant
7.4.1 Overview
7.4.2 Pre-Clinical Phase
7.4.3 Phase II
7.4.4 Phase III
7.5 R&D Pipeline – Kidney Transplant
7.5.1 Overview
7.5.2 Pre-Clinical Phase
7.5.3 Phase I
7.5.4 Phase II
7.5.5 Phase III
7.6 R&D Pipeline – Liver Transplant
7.6.1 Overview
7.6.2 Pre-Clinical Phase
7.6.3 Phase I
7.6.4 Phase II
7.6.5 Phase III
7.7 R&D Pipeline – Pancreas Transplant
7.7.1 Overview
7.7.2 Phase II
7.7.3 Phase III
8 Solid Organ Transplant Immunosuppressant Market to 2018 – Marketed Products
8.1 Prograf
8.1.1 Overview
8.1.2 Safety
8.1.3 Efficacy
8.2 Cellcept
8.2.1 Overview
8.2.2 Safety
8.2.3 Efficacy
8.3 Myfortic
8.3.1 Overview
8.3.2 Safety
8.3.3 Efficacy
8.4 Neoral
8.4.1 Overview
8.4.2 Safety
8.4.3 Efficacy
8.5 Zenapax
8.5.1 Overview
8.5.2 Safety
8.5.3 Efficacy
9 Solid Organ Transplant Immunosuppressant Market to 2018 – Competitive Landscape
9.1 F. Hoffman La Roche
9.1.1 Overview
9.1.2 Marketed Products
9.1.3 SWOT Analysis
9.2 Novartis AG
9.2.1 Overview
9.2.2 Marketed Products
9.2.3 SWOT Analysis
9.3 Genzyme Corporation
9.3.1 Overview
9.3.2 Marketed Products
9.3.3 SWOT Analysis
9.4 Astellas Pharma Inc.
9.4.1 Overview
9.4.2 Marketed Products
9.4.3 SWOT Analysis
10 Solid Organ Transplant Immunosuppressant Market to 2018 – Strategic Consolidations
10.1 Segmentation by Type
10.2 Segmentation by Year
10.3 Segmentation by Indication
10.4 Segmentation by Geography
10.5 Segmentation by Deal Value
10.6 Major M&As
10.7 Major Licensing Agreements
10.8 Major Co-Development Deals
11 Solid Organ Transplant Immunosuppressant Market to 2018-Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 Research Methodology
11.3.1 Coverage
11.3.2 Secondary Research
11.3.3 Primary Research
11.3.4 Therapeutic Landscape
11.3.5 Market Size by Geography
11.3.6 Geographical Landscape
11.3.7 Pipeline Analysis
11.3.8 Competitive Landscape
11.3.9 Expert Panel Validation
11.4 Contact Us
11.5 Disclaimer
11.6 Sources
List of Tables and Figures